

Roderick Beijersbergen (PhD) is group leader at the Netherlands Cancer Institute, and professor Functional Genomics at the University of Amsterdam. In 1999, he established his own research group at the Netherlands Cancer Institute in Amsterdam, with a focus on the development and application of large-scale functional genomic technologies, including RNAi and CRISPR, with the goal to identify novel and more effective cancer treatments. His group pioneered the pooled RNAi screening technology which has now been extended to CRISPR/CAS9 genome editing based screening. These pooled functional genomic screens have led to the identification of novel targets for cancer therapy, to the understanding of the mechanisms of action of novel drugs and the identification of novel mechanisms of acquired resistance to pathway targeted therapeutics. Based on the findings of these large-scale screening efforts, novel treatment combinations have been established and are currently under study in several clinical trials.